循环胺衍生物 (5e) 通过保护胰腺细胞和增强胰岛素分泌来减轻1型糖尿病大鼠的高血糖
Wael A Alanazi1, Ali H Alenezi2, Doaa M El-Nagar3
1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, 11451, Riyadh, Saudi Arabia. waalanazi@ksu.edu.sa.
概括
化合物5e在1型糖尿病 (T1D) 鼠标模型中有效降低血糖. 它还保护胰腺组织,显示出作为糖尿病管理的新型治疗剂的前景.
科学领域:
- 生物化学 生物化学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病是心血管疾病和死亡的主要原因.
- 之前的研究已经确定了循环胺化合物5e作为潜在的低血糖剂.
- 1型糖尿病 (T1D) 需要有效的治疗来控制高血糖并预防并发症.
研究的目的:
- 阐明化合物5e在T1D大鼠模型中改善高血糖的机制.
- 评估5e对代谢荷尔蒙和胰腺组织的影响.
- 评估5e对胰腺小岛的抗亡作用.
主要方法:
- 建立了一个T1D大鼠模型,并用化合物5e (10和15毫克/公斤) 或 glibenclamide (10毫克/公斤) 进行治疗.
- 血糖水平,葡萄糖耐受性和胰岛素敏感性在两周内被监测.
- 分析了胰岛素,葡萄糖和脂酶的血清水平,并对胰腺组织进行细胞灭绝的组织学检查.
主要成果:
- 5e和glibenclamide都使血糖降低了约36%;15 mg/kg 5e剂量实现了50%的降低.
- 化合物5e在葡萄糖耐受性测试中显著改善了血糖控制和胰岛素敏感性.
- 组织学分析显示,5e治疗减少了胰腺亡,改善了小岛形态,特别是在较高剂量时.
结论:
- 化合物5e显示出显著的低血糖效应,并增强T1D大鼠的葡萄糖代谢.
- 5e对胰腺β细胞亡具有保护性,可保护小岛的结构和功能.
- 这些发现支持5e化合物作为T1D新型治疗剂的潜力,值得进一步研究.
相关概念视频
Glucagon-like Receptor Agonists
809
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
809
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
Oral Hypoglycemic Agents: Glinides
554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
554
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
554
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K


